Target Price | $329.57 |
Price | $272.58 |
Potential | 20.91% |
Number of Estimates | 23 |
23 Analysts have issued a price target Amgen 2025 . The average Amgen target price is $329.57. This is 20.91% higher than the current stock price. The highest price target is $405.00 48.58% , the lowest is $195.00 28.46% . | |
A rating was issued by 34 analysts: 15 Analysts recommend Amgen to buy, 17 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Amgen stock has an average upside potential 2025 of 20.91% . Most analysts recommend the Amgen stock at Hold. |
27 Analysts have issued a sales forecast Amgen 2024 . The average Amgen sales estimate is $33.2b . This is 2.63% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $33.5b 3.75% , the lowest is $32.9b 1.78% .
This results in the following potential growth metrics:
2023 | $28.0b | 7.35% |
---|---|---|
2024 | $33.2b | 18.44% |
2025 | $34.3b | 3.51% |
2026 | $34.9b | 1.52% |
2027 | $35.5b | 1.86% |
2028 | $36.3b | 2.20% |
7 Analysts have issued an Amgen EBITDA forecast 2024. The average Amgen EBITDA estimate is $19.2b . This is 59.02% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $20.5b 69.34% , the lowest is $18.3b 51.47% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $12.4b | 1.91% |
---|---|---|
2024 | $19.2b | 55.54% |
2025 | $17.9b | 6.98% |
2026 | $17.8b | 0.27% |
2027 | $19.3b | 8.26% |
2028 | $19.7b | 2.06% |
2023 | 44.11% | 8.62% |
---|---|---|
2024 | 57.93% | 31.32% |
2025 | 52.06% | 10.13% |
2026 | 51.14% | 1.77% |
2027 | 54.36% | 6.30% |
2028 | 54.28% | 0.15% |
10 Amgen Analysts have issued a net profit forecast 2024. The average Amgen net profit estimate is $4.9b . This is 16.56% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $6.3b 49.30% , the lowest is $4.1b 2.89% .
This results in the following potential growth metrics and future Net Margins:
2023 | $6.7b | 3.14% |
---|---|---|
2024 | $4.9b | 27.11% |
2025 | $5.6b | 14.29% |
2026 | $6.5b | 16.05% |
2027 | $9.1b | 39.99% |
2028 | $10.0b | 9.74% |
2023 | 23.97% | 3.92% |
---|---|---|
2024 | 14.75% | 38.46% |
2025 | 16.29% | 10.44% |
2026 | 18.62% | 14.30% |
2027 | 25.59% | 37.43% |
2028 | 27.48% | 7.39% |
10 Analysts have issued a Amgen forecast for earnings per share. The average Amgen <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $9.10 . This is 16.52% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $11.66 49.30% , the lowest is $7.58 2.94% .
This results in the following potential growth metrics and future valuations:
2023 | $12.49 | 3.14% |
---|---|---|
2024 | $9.10 | 27.14% |
2025 | $10.41 | 14.40% |
2026 | $12.07 | 15.95% |
2027 | $16.90 | 40.02% |
2028 | $18.55 | 9.76% |
Current | 34.90 | 80.18% |
---|---|---|
2024 | 29.94 | 14.21% |
2025 | 26.20 | 12.49% |
2026 | 22.57 | 13.85% |
2027 | 16.13 | 28.53% |
2028 | 14.69 | 8.93% |
Based on analysts' sales estimates for 2024, the Amgen stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 5.97 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 4.42 .
This results in the following potential growth metrics and future valuations:
Current | 6.12 | 4.97% |
---|---|---|
2024 | 5.97 | 2.52% |
2025 | 5.76 | 3.39% |
2026 | 5.68 | 1.49% |
2027 | 5.57 | 1.83% |
2028 | 5.45 | 2.15% |
Current | 4.53 | 17.21% |
---|---|---|
2024 | 4.42 | 2.57% |
2025 | 4.27 | 3.39% |
2026 | 4.20 | 1.50% |
2027 | 4.13 | 1.82% |
2028 | 4.04 | 2.15% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.